{"mainPropery":{"diseaseId":7471,"diseaseName":"Progressive supranuclear palsy","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7471/progressive-supranuclear-palsy","synonyms":["Supranuclear palsy, progressive","PSP","Steele-Richardson-Olszewski Syndrome","Familial progressive supranuclear palsy (type)"],"synonyms-with-source":[{"name":"Supranuclear palsy, progressive"},{"name":"PSP"},{"name":"Steele-Richardson-Olszewski Syndrome"},{"name":"Familial progressive supranuclear palsy (type)"}],"identifiers":[{"identifierType":"OMIM","identifierId":"601104"},{"identifierType":"ORPHANET","identifierId":"683"}]},"diseaseCategories":[],"organizations":[{"resourceID":243,"resourceName":"CurePSP","abbreviation":"","address1":"1216 Broadway, 2nd Floor","address2":"","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10001","country":"United States","phone":"+1-347-294-2873 (CURE)","tty":"","tollFree":"1-800-457-4777","fax":"+1-410-785-7009","email":"info@curepsp.org","url":"https://www.psp.org/","freeText":""},{"resourceID":532,"resourceName":"Association for Frontotemporal Degeneration","abbreviation":"AFTD","address1":"2700 Horizon Drive, Suite 120","address2":"","address3":"","address4":"","address5":"","city":"King of Prussia","state":"PA","zip":"19406","country":"United States","phone":"+1-267-514-7221","tty":"","tollFree":"1-866-507-7222","fax":"","email":"info@theaftd.org","url":"https://www.theaftd.org/","freeText":""},{"resourceID":2354,"resourceName":"Parkinson's Patients Support Groups, Inc.","url":"http://www.ppsg.org"}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/601104' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='https://www.ncbi.nlm.nih.gov/pubmed/?term=Progressive+supranuclear+palsy' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Progressive supranuclear palsy. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Progressive+supranuclear+palsy%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Progressive supranuclear palsy. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/progressive-supranuclear-palsy' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Progressive supranuclear palsy. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1155,"resourceId":1835,"resourceName":"Identification of a Novel Risk Locus for Progressive Supranuclear Palsy by a Pooled Genomewide Scan of 500,288 Single-Nucleotide Polymorphisms","descriptionText":"Melquist, Stacey et.al., <a href='http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;pubmedid=17357082 ' target='_blank'>Identification of a Novel Risk Locus for Progressive Supranuclear Palsy by a Pooled Genomewide Scan of 500,288 Single-Nucleotide Polymorphisms</a>, <span class=\"citation-abbreviation\">Am J Hum Genet. </span><span class=\"citation-publication-date\">2007 April; </span><span class=\"citation-volume\">80</span><span class=\"citation-issue\">(4)</span><span class=\"citation-flpages\">: 769â€“778.</span>","resourceClassificationName":"Overview","resourceClassificationSectionName":"Selected Full-Text Journal Articles"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C0038868/' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/287/viewAbstract' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/progressivesupranuclearpalsy.html' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1530,"resourceId":2161,"resourceName":"National Institute of Neurological Disorders and Stroke (NINDS)","descriptionText":"The <a href='http://www.ninds.nih.gov/disorders/psp/detail_psp.htm' target='_blank'>National Institute of Neurological Disorders and Stroke</a> (NINDS) collects and disseminates research information related to neurological disorders. Click on the link to view information on&nbsp;this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/1151430-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1532,"resourceId":2163,"resourceName":"Social Security Administration","descriptionText":"The <a href='https://secure.ssa.gov/apps10/poms.nsf/lnx/0423022455' target='_blank'>Social Security Administration</a> has included this condition in their Compassionate Allowances Initiative. This initiative speeds up the processing of disability claims for applicants with certain medical conditions that cause severe disability. More information about <a href=\"http://www.ssa.gov/compassionateallowances/index.htm\" target=\"_blank\">Compassionate Allowances</a> and <a href=\"https://www.ssa.gov/benefits/disability/\" target=\"_blank\">applying for Social Security disability</a> is available online.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=683' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/books/NBK1505/' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1745,"resourceId":2899,"resourceName":"RDCRN - Frontotemporal Lobar Degeneration Clinical Research Consortium (FTLD CRC)","descriptionText":"The <a href=\"http://www.rarediseasesnetwork.org/cms/artfl/\" target=\"_blank\">Advancing Research and Treatment for Frontotemporal Lobar Degeneration Consortium</a> (ARTFL)\r\nis an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research on conditions that occur in association with frontotemporal lobar degeneration. The ARTFL has a contact registry for patients who wish to be contacted about clinical research opportunities and updates on the progress of the ARTFL research projects.\r\n<br />\r\n<br />\r\nFor more information on the registry see: <a target=\"_blank\" href=\"http://www.rarediseasesnetwork.org/cms/artfl/Get-Involved/Contact-Registry\">http://www.rarediseasesnetwork.org/cms/artfl/Get-Involved/Contact-Registry</a>","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:678' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":1158,"questionText":"What is progressive supranuclear palsy?","answerText":"<strong>Progressive supranuclear palsy (PSP)</strong> is a degenerative <a href=\"http://www.nlm.nih.gov/medlineplus/neurologicdiseases.html\" target=\"_blank\">neurologic disease</a> due to damage to nerve cells in the brain.[10490] Signs and symptoms vary but may include loss of balance; blurring of vision; problems controlling eye movement; changes in mood, behavior and judgment; cognitive decline; and slowing and slurred speech. PSP is often misdiagnosed as <a href=\"https://rarediseases.info.nih.gov/gard/10251/parkinson-disease/Resources/1\" target=\"_blank\">Parkinson disease</a> due to similar symptoms. Onset is usually after age 60 but may occur earlier. Most cases of PSP appear to be <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK5191/def-item/sporadic/\" target=\"_blank\">sporadic</a>, but familial cases have been reported. Some cases have been found to be caused by a <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutation</a> in the <em><a href=\"http://ghr.nlm.nih.gov/gene/MAPT\" target=\"_blank\">MAPT</a> </em>gene, and other genetic factors are being studied. There is currently no effective treatment for PSP, and symptoms usually do not respond to medications. Research regarding potential treatments is ongoing.[10490][10491]","dateModified":"2016-01-28T00:00:00"},"basicQuestions":[{"questionId":1159,"questionText":"What are the signs and symptoms of progressive supranuclear palsy?<br />","answerText":"Progressive supranuclear palsy (PSP) causes a wide range of symptoms that differ among affected people. Most commonly, the first symptom is losing balance while walking, which may cause unexplained falls. Other common early symptoms include changes in personality, mood and behavior; irritability; and forgetfulness.[10490]\r\n<p>As PSP progresses, most people develop blurring of vision and problems controlling eye movement. This can lead to involuntarily closing  the eyes; prolonged or infrequent blinking; or difficulty opening the eyes. Some people have trouble maintaining eye contact during a conversation.[10490]<br />\r\n<br />\r\nOther issues develop as the disease advances, including slow movement (bradykinesia), clumsiness, and stiffness. These problems worsen with time, with most affected people ultimately needing a wheelchair.[10492] Weakening of the muscles in the mouth, tongue and throat  lead to slurred speech and difficulty swallowing. This often causes aspiration pneumonia, the most common cause of death in people with PSP.[10490]</p>","dateModified":"2016-01-28T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":10490,"authors":"","articleTitle":"Progressive Supranuclear Palsy Fact Sheet","bookWebsiteJournalTitle":"NINDS","date":"November 5, 2015","volume":"","pages":"","url":"http://www.ninds.nih.gov/disorders/psp/detail_psp.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10492,"authors":"","articleTitle":"Progressive Supranuclear Palsy","bookWebsiteJournalTitle":"Genetics Home Reference","date":"May, 2015","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/progressive-supranuclear-palsy","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1160,"questionText":"What causes progressive supranuclear palsy?<br />","answerText":"While progressive supranuclear palsy (PSP) is usually <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK5191/def-item/sporadic/\" target=\"_blank\">sporadic</a>, some cases run in families. In most cases, the genetic cause is unknown, but some are due to <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a> or \"variations\" in the <em><a href=\"http://ghr.nlm.nih.gov/gene/MAPT\" tabindex=\"-1\" target=\"_blank\">MAPT</a> </em>gene.<br />\r\n<br />\r\nThe <em>MAPT</em> gene gives the body instructions to make a <a href=\"http://ghr.nlm.nih.gov/handbook/howgeneswork/protein\" target=\"_blank\">protein</a> called tau. This protein is found in nerve cells (neurons) in the brain and in other parts of the nervous system. It plays a part in putting together and stabilizing components of the structure of cells, helping cells to keep their shape, and aiding in cell division and the transport of materials. It appears that gene mutations or variations that affect the function of the tau protein cause PSP, or cause an increased risk for a person to develop PSP.<br />\r\n<br />\r\nAbnormal tau is also found in people with PSP who don't have <em>MAPT</em> mutations. Therefore, researchers think that additional genetic and environmental factors contribute to the development of PSP. However, other specific genes that may be involved have not yet been identified.[10492]","dateModified":"2016-01-29T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":10492,"authors":"","articleTitle":"Progressive Supranuclear Palsy","bookWebsiteJournalTitle":"Genetics Home Reference","date":"May, 2015","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/progressive-supranuclear-palsy","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":7677,"questionText":"Is progressive supranuclear palsy inherited?","answerText":"Progressive supranuclear palsy (PSP) is usually a <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK5191/def-item/sporadic/\" tabindex=\"-1\" target=\"_blank\">sporadic</a> condition (not inherited), occurring in people with no family history of PSP. However, in more recent years it has been found that in rare cases, PSP is familial. It has also been found that some people with PSP have close relatives with dementia or parkinsonism.[10491]<br />\r\n<br />\r\nCases of familial PSP caused by a <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutation</a> in the <em><a href=\"http://ghr.nlm.nih.gov/gene/MAPT\" target=\"_blank\">MAPT</a></em> gene have been reported. <em>MAPT</em> mutations are also known to be responsible for other familial tauopathies. Currently, the proportion of people with PSP who have a <em>MAPT</em> mutation is unknown.[10491]<br />\r\n<br />\r\nPSP caused by <em>MAPT</em> mutations is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=\"_blank\">autosomal dominant</a> manner. This means that having a mutation in only one copy of the <a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" target=\"_blank\">gene</a> in each cell is enough to cause features of the condition. In some cases, an affected person inherits the mutated gene from an affected parent. In other cases, the mutation occurs for the first time in a person with no family history of the condition. This is called a <em><a href=\"http://www.ncbi.nlm.nih.gov/books/NBK5191/def-item/de-novo-mutation/\" target=\"_blank\">de novo</a></em> mutation.<br />\r\n<br />\r\nWhen a person with a mutation causing an autosomal dominant condition has children, each child has a 50% (1 in 2) chance to inherit that mutation.<br />\r\n<br />\r\nWhile other locations on chromosomes have been linked to familial PSP, to our knowledge, no other causative genes have been identified. There may also be genes (including <em>MAPT</em>) in which \"variants\" increase a person's risk to develop PSP. In these cases, the condition itself is not inherited, but a predisposition to developing PSP or a related condition may be inherited.[7616]<br />\r\n<br />\r\n<strong>Because there are likely unidentified genetic causes of PSP, if the genetic cause in a family is unknown, we cannot estimate the likelihood that PSP might recur.</strong>  Our understanding of the genetics of PSP is expanding, and studies are ongoing.[10491]<br />\r\n<br />\r\nPeople with a personal or family history of PSP with questions about recurrence risks or genetic testing are encouraged to speak with a genetics professional.","dateModified":"2016-01-29T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":7616,"authors":"","articleTitle":"Progressive supranuclear palsy","bookWebsiteJournalTitle":"NORD","date":"2014","volume":"","pages":"","url":"http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/287/viewAbstract","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10491,"authors":"Im SY, Kim YE, Kim YJ","articleTitle":"Genetics of Progressive Supranuclear Palsy","bookWebsiteJournalTitle":"J Mov Disord","date":"September, 2015","volume":"8(3)","pages":"122-129","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10037,"questionText":"Is genetic testing available for progressive supranuclear palsy?","answerText":"Progressive supranuclear palsy (PSP) is usually <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK5191/def-item/sporadic/\" target=\"_blank\">sporadic</a> (not inherited), but in rare cases it can be inherited. While the genetic cause of PSP not usually known, it can be caused by a <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutation</a> in a gene called <em><a href=\"http://ghr.nlm.nih.gov/gene/MAPT\" target=\"_blank\">MAPT</a></em>. To our knowledge, <em>MAPT</em> is currently the only gene for which clinical genetic testing for PSP is available. This means that <strong>if a person with PSP is found to have a disease-causing mutation in the <em>MAPT</em> gene, genetic testing of other family members for the same mutation in this gene may be available</strong>. Each child of a person with PSP caused by a <em>MAPT</em> mutation has a 50% chance to inherit the mutated gene. However, if a person with PSP does not have a mutation in the <em>MAPT</em> gene (which is most often the case), clinical genetic testing for other family members is not available.<br />\r\n<br />\r\nThe <a href=\"http://www.ncbi.nlm.nih.gov/gtr/conditions/C0038868/\" target=\"_blank\">Genetic Testing Registry</a> (GTR) provides information about the genetic tests available for PSP. People interested in genetic testing for PSP are encouraged to speak with a genetics professional for additional information.","dateModified":"2016-01-31T00:00:00","resourceClassificationName":"Diagnosis","references":[]},{"questionId":1161,"questionText":"How is progressive supranuclear palsy diagnosed?<br />","answerText":"Progressive supranuclear palsy (PSP) is often hard to diagnose because its symptoms can be similar to those of other, more common movement disorders. It may also be hard to diagnose because some of the most characteristic symptoms may develop late, or not at all.[10502]<br />\r\n<br />\r\nA diagnosis of PSP is currently based on the signs and symptoms present (clinical features).[10502] Identifying early gait instability and difficulty moving the eyes (the hallmark of the disease), as well as ruling out other conditions, are most important.[10490] There is no laboratory test or imaging study that is diagnostic. Identifying neurofibrillary tangles (aggregates of tau) in their characteristic distribution aids in the diagnosis.[10502]","dateModified":"2016-01-29T00:00:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":10490,"authors":"","articleTitle":"Progressive Supranuclear Palsy Fact Sheet","bookWebsiteJournalTitle":"NINDS","date":"November 5, 2015","volume":"","pages":"","url":"http://www.ninds.nih.gov/disorders/psp/detail_psp.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10502,"authors":"Stewart A Factor, Christine Doss Esper","articleTitle":"Progressive supranuclear palsy (PSP)","bookWebsiteJournalTitle":"UpToDate","date":"December, 2015","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"Waltham, MA","publisher":"UpToDate"}]},{"questionId":1162,"questionText":"How might progressive supranuclear palsy be treated?<br />","answerText":"There are currently no treatments that alter the course of disease for people with progressive supranuclear palsy (PSP), and no drugs that provide significant relief of symptoms.[10502] However, supportive treatment may be helpful and may include:<br />\r\n<ul>\r\n    <li>Management of dysphagia and dysarthria with the help of dietitians as well as speech and language therapists</li>\r\n    <li>Early occupational therapy to promote longer independence in performing activities of daily living</li>\r\n    <li>The use of mirror-prism lenses for those with severe limitation of extraocular movements to read and feed themselves </li>\r\n    <li>The use of eyelid crutches, alone or in combination with botox therapy, for inability to open the eyes and <a href=\"https://nei.nih.gov/health/blepha/blepharospasm\" tabindex=\"-1\" target=\"_blank\">blepharospasm</a></li>\r\n    <li>Physical therapy for symptomatic treatment of postural instability and falls, including gait and balance training[10502]</li>\r\n</ul>\r\n<p>A surgical procedure called a <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002937.htm\" target=\"_blank\">gastrostomy</a> may be necessary when there are swallowing disturbances or a high risk of severe choking.[10490]</p>","dateModified":"2016-01-29T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":10490,"authors":"","articleTitle":"Progressive Supranuclear Palsy Fact Sheet","bookWebsiteJournalTitle":"NINDS","date":"November 5, 2015","volume":"","pages":"","url":"http://www.ninds.nih.gov/disorders/psp/detail_psp.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10502,"authors":"Stewart A Factor, Christine Doss Esper","articleTitle":"Progressive supranuclear palsy (PSP)","bookWebsiteJournalTitle":"UpToDate","date":"December, 2015","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"Waltham, MA","publisher":"UpToDate"}]},{"questionId":1163,"questionText":"What is the long-term outlook for people with progressive supranuclear palsy?","answerText":"Progressive supranuclear palsy (PSP) gets progressively worse.[10490] Most people become dependent for care within three or four years from onset, and quality of life is significantly reduced.[10502] However, with good attention to medical and nutritional needs, it is possible for many people with PSP to live a decade or more after the first symptoms appear. The condition predisposes people to serious complications such as pneumonia (the most common cause of death) secondary to difficulty in swallowing (<a href=\"http://www.nidcd.nih.gov/health/voice/dysph.asp\" target=\"_blank\">dysphagia</a>). Other complications that people may experience include choking, head injury, and fractures caused by falls.[10490]","dateModified":"2016-01-29T00:00:00","resourceClassificationName":"Prognosis","references":[{"referenceId":10490,"authors":"","articleTitle":"Progressive Supranuclear Palsy Fact Sheet","bookWebsiteJournalTitle":"NINDS","date":"November 5, 2015","volume":"","pages":"","url":"http://www.ninds.nih.gov/disorders/psp/detail_psp.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10502,"authors":"Stewart A Factor, Christine Doss Esper","articleTitle":"Progressive supranuclear palsy (PSP)","bookWebsiteJournalTitle":"UpToDate","date":"December, 2015","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"Waltham, MA","publisher":"UpToDate"}]}],"references":[],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":15302,"phenoTypeName":"Abnormal synaptic transmission","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13402,"phenoTypeName":"Dysphagia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":5233,"phenoTypeName":"Falls","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":11798,"phenoTypeName":"Impulsivity","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":14312,"phenoTypeName":"Neuronal loss in central nervous system","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13848,"phenoTypeName":"Postural instability","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10097,"phenoTypeName":"Supranuclear ophthalmoplegia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":11410,"phenoTypeName":"Unsteady gait","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":5157,"phenoTypeName":"Aphasia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10115,"phenoTypeName":"Blepharospasm","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13456,"phenoTypeName":"Bradykinesia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13743,"phenoTypeName":"Cerebral cortical atrophy","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14142,"phenoTypeName":"Delayed speech and language development","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":6011,"phenoTypeName":"Depressivity","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13847,"phenoTypeName":"Gliosis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11437,"phenoTypeName":"Memory impairment","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13872,"phenoTypeName":"Pseudobulbar signs","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5622,"phenoTypeName":"Slow saccadic eye movements","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5617,"phenoTypeName":"Vertical supranuclear gaze palsy","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":6020,"phenoTypeName":"Dementia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13451,"phenoTypeName":"Rigidity","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9423,"phenoTypeName":"Tremor","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":14136,"phenoTypeName":"Frontal release signs","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":5213,"phenoTypeName":"Limb dystonia","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":6254,"phenoTypeName":"Adult onset","percentRanges":"-"},{"phenoTypeId":11397,"phenoTypeName":"Akinesia","percentRanges":"-"},{"phenoTypeId":14134,"phenoTypeName":"Apathy","percentRanges":"-"},{"phenoTypeId":6539,"phenoTypeName":"Autosomal dominant inheritance","percentRanges":"-"},{"phenoTypeId":14313,"phenoTypeName":"Axial dystonia","percentRanges":"-"},{"phenoTypeId":10096,"phenoTypeName":"Blurred vision","percentRanges":"-"},{"phenoTypeId":10125,"phenoTypeName":"Diplopia","percentRanges":"-"},{"phenoTypeId":8703,"phenoTypeName":"Dysarthria","percentRanges":"-"},{"phenoTypeId":10134,"phenoTypeName":"Eyelid apraxia","percentRanges":"-"},{"phenoTypeId":5201,"phenoTypeName":"Frontolimbic dementia","percentRanges":"-"},{"phenoTypeId":13822,"phenoTypeName":"Gait imbalance","percentRanges":"-"},{"phenoTypeId":14311,"phenoTypeName":"Granulovacuolar degeneration","percentRanges":"-"},{"phenoTypeId":10038,"phenoTypeName":"Irritability","percentRanges":"-"},{"phenoTypeId":11395,"phenoTypeName":"Mutism","percentRanges":"-"},{"phenoTypeId":13857,"phenoTypeName":"Neurofibrillary tangles","percentRanges":"-"},{"phenoTypeId":1132,"phenoTypeName":"Neuronal loss in basal ganglia","percentRanges":"-"},{"phenoTypeId":9388,"phenoTypeName":"Parkinsonism","percentRanges":"-"},{"phenoTypeId":9198,"phenoTypeName":"Photophobia","percentRanges":"-"},{"phenoTypeId":14315,"phenoTypeName":"Retrocollis","percentRanges":"-"},{"phenoTypeId":9187,"phenoTypeName":"Supranuclear gaze palsy","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Progressive_supranuclear_palsy"}